PEIJIA-B (09996) has announced its interim results for 2026, with revenue reaching RMB 425 million, representing a year-on-year increase of 20.1%. Gross profit climbed 17.13% to RMB 290 million, while research and development expenses amounted to RMB 88.409 million.
According to the company's announcement, the group achieved sustained revenue growth during the reporting period. Through continuous optimization of its product portfolio, implementation of lean cost management measures, and enhancement of operational efficiency, the group partially offset the negative impacts arising from TAVR price adjustments, higher initial manufacturing costs during the TaurusTrio® production ramp-up phase, and volume-based procurement in its neurointerventional business—all while maintaining a stable gross margin of approximately 68.3%.
During the reporting period, the group's self-developed neurointerventional products continued to gain market recognition, driven by differentiated product design, clinical value, and innovative treatment solutions. Through close collaboration between physicians and engineers, the group has developed a series of innovative technologies and solutions. Notably, the BASIS technique based on the Syphonet® thrombectomy stent and the zero-exchange technique utilizing the Fastunnel® delivery balloon dilation catheter have achieved widespread clinical application, further driving market penetration of the related products. Additionally, the DCwire® micro-guidewire has continued to receive clinical endorsement, contributing to the growth of the group's self-developed neurointerventional product portfolio.
At the same time, the group has continued to expand its neurointerventional product portfolio through strategic partnerships. During the reporting period, the YonFlow® flow diversion stent and Qida® disposable neurovascular sheath—for which the group holds exclusive distribution rights in China—achieved increased commercialization scale and contributed additional revenue growth. The group also entered into a strategic cooperation agreement with B. Braun Medical (Shanghai) International Trading Co., Ltd. (B. Braun Medical) for exclusive distribution of the SeQuent® Please CIS paclitaxel drug-coated intracranial balloon dilation catheter in mainland China. This partnership further enriches the neurointerventional product pipeline and is expected to provide additional growth opportunities for the business upon obtaining regulatory approval in the future.